Tatiana Novobrantseva, Ph.D.

Dr. Novobrantseva is Chief Scientific Officer at NextPoint Therapeutics, bringing deep expertise in immunology, immuno-oncology, autoimmunity, and fibrosis with an outstanding track record in drug development and antibody development. She co-founded Verseau Therapeutics in 2017, where she served as Chief Scientific Officer for over five years, advancing immunotherapies that stimulate macrophage repolarization to initiate anti-cancer immune responses. Prior to that, she led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research.

Dr. Novobrantseva earned her PhD from the University of Cologne in Germany and completed postdoctoral research at Harvard Medical School in Dr. Klaus Rajewsky’s laboratory, focusing on B cell immunology and autoimmunity. She has advanced through industry roles as a scientist at Biogen and Alnylam Pharmaceuticals, and served as Director of Research at Jounce Therapeutics, where she led programs to reactivate the immune system against cancer.

She currently serves on the Scientific Advisory Boards of Voro Therapeutics and FairJourney Biologics, and on the Advisory Board for Women in the Enterprise of Science and Technology. Dr. Novobrantseva is also an advisor to Verseau Therapeutics.